HEXADRONE
11.12.2023 08:31:35 CET | Business Wire | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH.
The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more.
“Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European airspace legally, in accordance with categories C5 and C6, from 2024.
The exceptional modularity of the TUNDRA 2 offers reliable technical solutions for a variety of sectors. Due to its standardized interfaces, it can be easily extended using a multitude of addons while maintaining its compliance with current standards,”- says Alexandre Labesse, CEO of Hexadrone.
NavCert GmbH (NB 2603), currently chairs the coordination group of notified bodies for unmanned aircraft systems in accordance with the Delegated Regulation(EU) 2019/945. NavCert GmbH is one of the three entities in Europe which are appointed to perform C5/C6 class drone conformity tests, to be operated within the category specific, for performing operations Beyond Ground Observation (BGO) also known as Beyond Vision Line Of Sight (BVLOS).
Marcel Visser, CEO of NavCert GmbH, stated, “Congratulations to Hexadrone on being first confirming both multicopter C5 and C6 Drone specification compliancy to Delegated Regulation (EU) 2019/945. We are honored to be the Notified Body (NB 2603) selected by Hexadrone to perform Type Examinations for both version of the Tundra 2. Our extensive experience and our contribution to the development of the EN 4709 standard have been invaluable in conducting the technical assessments on unmanned aircraft systems for civil use. We remain dedicated to upholding the requisite standards of quality and safety for drone operations within the European Union."
*****
Starting 2024, Hexadrone is accelerating it’s worldwide expansion by selecting and recruiting Specialised resellers over the Globe.
About Hexadrone
Through its three Departments, Hexadrone is recognized as an expert in designing and manufacturing a modular UAV that gives customers a valuable investment for their activity. Founded in 2014, Hexadrone was initially providing a web platform to resel UAV components and quickly moved to the UAV custom assembling. Based on the user’s experiences feedback, Hexadrone has understood that a universal and modular platform was the answer to the market and after the first Version of the TUNDRA Hexadrone has built a factory to design and to manufacture a multi-purpose drone for professionals.
Today, the production capacity allowed to manufacture up to 1000 TUNDRA 2 units per year.
About NavCert GmbH
NavCert is the first laboratory ever accredited in Europe in the field of GNSS, nowadays with a flexible scope, a remarkable USP achievement. The firm provides worldwide technical services, like expert opinion, verification, validation, and voluntary certification services in the areas of precise positioning/localization, navigation, velocity and timing. Furthermore, NavCert is accredited as certification body for unmanned aircraft systems (UAS) by the Deutsche Akkreditierungsstelle (DAkkS) and is notified (NB 2603) by the German Federal Office of Civil Aeronautics for the EU Type Examination of fixed-wing, copter and multicopter UAS in classes C0 to C4 in the Open Category and C5 to C6 in the Specific Category according to the Delegated Regulation (EU) 2019/945 incl. referred standards. NavCert chairs the coordination group of notified bodies for UAS. These activities are complemented by GAP analysis of specification and documentation and pre-testing. For additional information, please visit NavCert website at www.navcert.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231210550915/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom